SCHEMBL10112833

SCHEMBL10112833

COc1ccc(OC=O)nc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.38
ALDH1A1 P00352 5/20 0.35
TSHR P16473 1/20 0.35
PRKDC P78527 1/20 0.34
NQO2 P16083 3/20 0.34
FDPS P14324 1/20 0.34
AOX1 Q06278 1/20 0.33
APP P05067 2/20 0.32
POLB P06746 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CTSA P10619 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394372 0.81 POLB (0.41) ERN1ALDH1A1NQO2POLBTDP1
SCHEMBL31414709 0.81 POLB (0.41) ERN1ALDH1A1NQO2POLBTDP1
SCHEMBL5490830 0.74 PRKDC (0.44) ERN1ALDH1A1TSHRPRKDCNQO2
SCHEMBL15043880 0.73 NPC1 (0.44) ALDH1A1PRKDCPOLBL3MBTL1TDP1
SCHEMBL17877757 0.73 MAPT (0.44) ERN1ALDH1A1POLBL3MBTL1KDM4E
SCHEMBL31651912 0.71 PDE4B (0.35) TSHRNQO2KDM4ECTSA
SCHEMBL2144116 0.70 S1PR4 (0.43) ALDH1A1NQO2L3MBTL1KDM4ECA12
SCHEMBL29769759 0.70 S1PR4 (0.43) ALDH1A1NQO2L3MBTL1KDM4ECA12
SCHEMBL28043667 0.69 BTK (0.41) ALDH1A1POLBTDP1KDM4E
SCHEMBL3792156 0.69 S1PR4 (0.47) ALDH1A1TSHRNQO2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 ERN1 2641/4885ALDH1A1 1104/4885TSHR 3563/4885
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 ERN1 2562/4885ALDH1A1 1148/4885TSHR 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.